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Abstract
Background: An accurate gene expression quantification using TaqMan Arrays (TA) could be
limited by the low RNA quantity obtained from some clinical samples. The novel cDNA
preamplification system, the TaqMan PreAmp Master Mix kit (TPAMMK), enables a multiplex
preamplification of cDNA targets and therefore, could provide a sufficient amount of specific
amplicons for their posterior analysis on TA.
Findings: A multiplex preamplification of 47 genes was performed in 22 samples prior to their
analysis by TA, and relative gene expression levels of non-preamplified (NPA) and preamplified (PA)
samples were compared. Overall, the mean cycle threshold (CT) decrement in the PA genes was
3.85 (ranging from 2.07 to 5.01). A high correlation (r) between the gene expression measurements
of NPA and PA samples was found (mean r = 0.970, ranging from 0.937 to 0.994; p < 0.001 in all
selected cases). High correlation coefficients between NPA and PA samples were also obtained in
the analysis of genes from degraded RNA samples and/or low abundance expressed genes.
Conclusion: We demonstrate that cDNA preamplification using the TPAMMK before TA analysis
is a reliable approach to simultaneously measure gene expression of multiple targets in a single
sample. Moreover, this procedure was validated in genes from degraded RNA samples and low
abundance expressed genes. This combined methodology could have wide applications in clinical
research, where scarce amounts of degraded RNA are usually obtained and several genes need to
be quantified in each sample.
Findings
Background
TaqMan Arrays (TAs) have recently been introduced as a
novel approach to measure gene expression. They com-
bine the high sensitivity provided by the real time quanti-
tative reverse-transcription polymerase chain reaction
(qRT-PCR) with the ability to simultaneously assay RNA
expression levels of up to 384 target genes in a single sam-
ple [1,2]. However, an accurate quantification with this
approach could be limited by the low sample amount
commonly encountered in clinical research. Therefore, it
is necessary to preamplify samples to generate enough
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cDNA copies to enable an accurate quantification of tran-
scripts and maintain high sensitivity.
Most of the current protocols for increasing small
amounts of mRNA are designed to globally amplify all the
transcriptome instead of the specific targets of interest and
are usually validated by DNA array, which is a more
imprecise methodology than qRT-PCR to quantify indi-
vidual genes [3,4].
Recently, a novel system, the TPAMMK, to increase cDNA
quantity prior to gene expression analysis by conventional
quantitative PCR has been described [5-8]. However,
there is no study validating this approach prior to gene
expression quantification by means of TA. The possibility
of simultaneously measuring gene expression of dozens
to hundreds of genes in those samples that yield scarce
quantities of RNA would be of great interest.
Here, we evaluate this cDNA preamplification system
(TPAMMK) prior to gene expression quantification by TA.
We test the approach in the context of bladder cancer
detection, by analyzing RNA samples obtained from blad-
der fluids. Furthermore, this type of sample provides us
the possibility to analyze the reliability of this combined
methodology for preamplifying cDNA from degraded
RNA samples and/or low abundance expressed genes.
Results and discussion
One of the major drawbacks for the clinical use of RNA
based techniques is the difficulty of obtaining sufficient
quantities of high quality RNA from some human sam-
ples. The novel multiplexed miniaturized format pro-
vided by TAs could be limited by the scarce quantities of
isolated RNA, since the sample is divided into a large
number of aliquots [9]. Several strategies for amplifying
RNA [10-12] or cDNA have been described [5-8,13,14],
but to date, there is no published study validating that
cDNA preamplification prior to TA analysis provides a
reliable representation of gene expression profiling.
In this study, we have used the TPAMMK (AB) to pream-
plify 47 genes in 22 bladder fluids samples prior to their
analysis by TA. This preamplification process allowed us
to load a 30 fold greater quantity of cDNA in each TA port
(500 ng for NPA vs ~15000 ng for PA samples) which
should theoretically result in a decrement of 4.9 CTs.
However, we found an overall mean CT decrement of 3.85
(ranging from 2.07 to 5.01) in PA samples (Table 1).
Although variations in amplification efficiencies (AE) of
the primers/probe sets used in TA methodology have been
found in this study and others [1], they do not help to
explain differences between the theoretical and the exper-
imental CT decrement described, since there is no signifi-
cant correlation between the experimental CT decrement
and the primers/probe set AE, neither before (r = 0.062; p
= 0.678) nor after (r = 0.060; p = 0.097) the cDNA pream-
plification process (Table 1).
On the other hand, linear regression analysis showed a
high correlation (r) between gene expression measure-
ments of NPA and PA samples for the validated genes
(mean r values = 0.970, ranging from 0.937 to 0.994, p <
0.001 in all cases, except for sample number 15 where
only 3 genes could be analyzed) (Table 2). Thus, albeit CT
decrement for each individual gene is not uniform, the
overall relative gene expression levels in PA samples
remained proportional to the original gene expression
levels in NPA samples. However, when checking pream-
plification uniformity individually for each gene (ΔΔCT
values within ± 1.5) we found that there were three genes
(IGF2, FGFR3 and CRH) that were consistently non-uni-
formly preamplified in a significant number of samples
and therefore were not suitable for preamplification
(Table 2). We do not have a clear explanation for this fact,
although transcript abundance, primers and probe locali-
zation or amplicon length/sequence could influence the
preamplification efficiency. From these results, it becomes
clear that cDNA preamplification before gene expression
quantification by TA can facilitate the analysis of multiple
target genes from very low quantities of RNA in a single
experiment. However, checking the preamplification uni-
formity in each target gene with control material before its
evaluation in testing samples is mandatory.
As the described CT decrement would not be sufficient to
accurately quantify gene expression in some cases, it must
be mentioned that, according to kit manufacturers, it is
possible to perform up to 14 preamplification cycles, as
well as to increase the quantity of cDNA in the preampli-
fication reaction up to 250 ng or to load more preampli-
fied volume of cDNA into each TA port to achieve the
desired decrement.
Since our goal was to test the suitability of the cDNA
preamplification of specific target genes before their quan-
tification by TA, we have only analyzed those genes with
a reliable CT value in NPA samples (CT ≥ 31). However,
to determine the linearity of the cDNA preamplification
in low abundant expressed genes (those target genes with
a CT value > 31 in NPA samples), we performed two serial
dilutions (1/20 and 1/400) of 3 cDNAs from NPA sam-
ples with different RNA degradation levels (sample
number 2, 11 and 22) and preamplified them with the
same protocol used for the non diluted NPA samples.
Subsequently, we compared the ΔCT values from diluted
PA samples with the corresponding ΔCT of the initial
cDNA (non diluted NPA) samples. This comparison
yielded correlation coefficients close to 1, indicating that
the vast majority of low abundant expressed genes are cor-B
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Table 1: Mean CT and mean AE for the 46 bladder cancer related genes and the endogenous control GUSB obtained before and after cDNA preamplification.
Gene 
symbol
Primer/probe set 
(AB)
Validated samples NPA samples PA samples Mean Ct 
decrement
r NPA samples PA samples
n NPA n PA Mean Ct St Dev Mean Ct St Dev Mean AE St Dev Mean AE St Dev
ANK2 Hs00153998_m1 1 18 29,22 - 25,90 - 3,32 - 1,889 - 1,794 -
ANLN Hs00218803_m1 17 20 28,50 1,58 23,97 1,64 4,53 0,966 1,807 0,06 1,834 0,09
ANXA10 Hs00200464_m1 16 20 27,19 2,83 22,87 2,45 4,32 0,992 1,987 0,05 1,962 0,08
ASAM Hs00293345_m1 3 15 29,39 1,08 25,31 0,93 4,09 0,965 1,926 - 1,752 -
ASPM Hs00411505_m1 16 21 27,88 1,63 23,93 1,52 3,95 0,978 1,897 0,05 1,838 0,09
C14orf78 Hs00746838_s1 16 22 28,65 1,78 24,56 1,52 4,09 0,991 1,933 0,06 1,796 0,09
CCNA2 Hs00153138_m1 17 20 28,65 1,78 25,22 1,74 3,42 0,93 1,821 0,03 1,688 0,06
CDC2 Hs00364293_m1 16 20 28,47 1,77 23,86 1,74 4,61 0,96 1,867 0,06 1,823 0,09
CDC20 Hs00415851_g1 20 20 28,09 2,19 24,09 2,12 4,01 0,973 1,816 0,05 1,803 0,09
CDCA1 Hs00230097_m1 13 20 28,76 1,40 24,37 1,26 4,40 0,944 1,944 0,02 1,768 0,10
CENPF Hs00193201_m1 16 21 28,20 1,65 24,55 1,58 3,65 0,96 1,898 0,04 1,840 0,10
CFH Hs00164830_m1 19 22 26,66 2,40 22,71 2,15 3,95 0,978 1,832 0,04 1,786 0,02
CRH Hs00174941_m1 9 11 25,42 2,67 23,01 2,31 2,40 0,967 1,836 0,06 1,711 0,11
CTSE Hs00157213_m1 19 21 25,60 3,52 21,38 3,38 4,22 0,997 1,858 0,05 1,842 0,03
CYP24A1 Hs00167999_m1 19 21 26,40 3,11 22,62 2,93 3,78 0,994 1,944 0,07 1,940 0,08
EBF Hs00395513_m1 3 14 29,87 0,67 26,27 0,44 3,60 0,817 1,665 - 1,651 -
FGFR3 Hs00179829_m1 18 20 23,88 2,76 21,26 2,67 2,62 0,967 1,833 0,04 1,753 0,07
FOXM1 Hs00153543_m1 15 20 28,38 2,00 24,67 1,88 3,71 0,971 1,896 0,05 1,718 0,05
GJB2 Hs00269615_s1 21 22 26,13 2,39 22,27 2,36 3,86 0,984 1,864 0,05 1,888 0,06
GUSB Hs99999908_m1 22 22 25,18 2,08 20,79 2,14 4,40 - 1,914 0,04 1,942 0,07
IGF2 Hs00171254_m1 18 21 25,15 3,98 23,08 3,90 2,07 0,993 1,835 0,06 1,743 0,07
IQGAP3 Hs00603642_m1 14 20 28,29 1,52 24,18 1,49 4,11 0,978 1,886 0,03 1,782 0,04
KIF20A Hs00194882_m1 12 20 28,11 1,47 24,26 1,47 3,85 0,982 1,905 0,03 1,786 0,08
KIF2C Hs00199232_m1 17 21 27,97 1,87 23,88 1,93 4,09 0,966 1,804 0,05 1,739 0,06
KIF4A Hs00602211_g1 13 20 28,27 1,56 24,02 1,37 4,25 0,968 1,872 0,07 1,797 0,08
KLF9 Hs00230918_m1 21 22 27,60 1,66 23,65 1,54 3,95 0,955 1,793 0,08 1,805 0,07
KRT14 Hs00265033_m1 12 20 29,12 1,34 25,66 1,54 3,45 0,97 1,995 0,08 1,780 0,15
KRT20 Hs00300643_m1 19 21 23,21 3,05 19,54 2,84 3,66 0,986 1,977 0,05 2,019 0,08
MAGEA3 Hs00366532_m1 5 8 28,01 0,44 24,50 0,73 3,51 0,935 1,790 0,05 1,747 0,03
MAGEA9 Hs00245619_s1 13 21 27,44 1,74 23,99 1,66 3,45 0,986 1,874 0,02 1,736 0,07
MCM10 Hs00218560_m1 9 20 28,82 1,09 25,16 1,12 3,66 0,968 1,861 0,03 1,694 0,03
MELK Hs00207681_m1 13 20 28,33 1,58 24,83 1,60 3,50 0,932 1,821 0,07 1,671 0,10
MMP1 Hs00233958_m1 18 21 26,04 2,92 22,34 2,91 3,71 0,986 1,686 0,06 1,640 0,07
MMP12 Hs00159178_m1 12 18 28,19 2,17 23,17 2,11 5,01 0,987 1,846 0,11 1,818 0,09
NEK2 Hs00601227_mH 12 21 28,78 1,56 24,39 1,47 4,38 0,963 1,737 0,06 1,773 0,09
NR2F1 Hs00818842_m1 6 19 29,08 1,52 24,77 1,51 4,31 0,984 1,845 0,05 1,790 0,01
PDZRN3 Hs00392900_m1 10 22 26,72 2,07 23,11 1,74 3,61 0,99 1,888 0,05 1,736 0,11
POLQ Hs00198196_m1 10 19 29,47 1,09 24,98 1,20 4,49 0,914 1,807 0,07 1,608 0,15
POSTN Hs00170815_m1 4 12 28,96 1,45 24,70 1,47 4,26 0,983 1,904 0,09 1,837 0,12
PPIA Hs99999904_m1 22 22 21,54 2,32 17,76 2,29 3,78 0,927 1,912 0,04 1,991 0,10
PPP1R14D Hs00214613_m1 8 18 28,18 2,05 24,29 1,68 3,89 0,989 1,886 0,07 1,833 0,14
PTPRC Hs00236304_m1 22 22 25,15 2,03 21,62 2,18 3,53 0,986 1,944 0,06 1,886 0,09
SLC1A6 Hs00192604_m1 7 12 27,54 2,05 23,63 1,34 3,92 0,978 1,743 0,03 1,683 0,02
TERT Hs00162669_m1 2 12 29,40 1,13 26,10 1,64 3,31 - 1,856 - 1,697 -
TOP2A Hs00172214_m1 19 20 27,40 2,42 23,31 2,27 4,09 0,909 1,890 0,06 1,873 0,09
TPX2 Hs00201616_m1 18 20 27,69 2,17 23,91 2,04 3,78 0,968 1,990 0,07 1,931 0,07
TRIP13 Hs00188500_m1 18 20 28,03 1,96 23,83 1,90 4,21 0,976 1,893 0,05 1,806 0,05
Key: CT, Cycle Threshold; AE, Amplification Efficiency; NPA, Non-Preamplified; PA, Preamplified; St Dev, Standard Deviation.B
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Table 2: Summary of the clinical characteristics, RNA quality and cDNA preamplification results for the 22 samples analyzed in this study.
Sample 
number
Type of 
sample
Type of 
bladder 
fluid
Tumor 
characteristics
RNA characteristics N° validated genes 
(CT ≤ 31)
Correlation 
coeficients 
(r)
N° validated genes in 
NPA samples with 
ΔΔCT outside ± 1.5
Gene symbol
rRNA 
ratio
RIN % of total
stage grade 18S 
area
28S 
area
NPA 
samples
PA 
samples
1 T BW Ta LG 2 9.8 20.6 40.4 33 43 0.986 1 IGF2
2 T BW Ta LG 1.7 9.2 18.5 31.6 39 46 0.978 4 CRH, FGFR3, 
IGF2,KRT14
3 T BW Ta LG 1.7 8.9 18.5 32.1 38 45 0.987 2 CRH,IGF2
4 T BW Ta LG 1.6 8.8 17.0 26.8 36 45 0.991 1 IGF2
5 T BW Ta LG 1.3 8.2 14.2 18.1 25 42 0.987 1 IGF2
6 T BW T2b+CIS HG 1.8 8 9.3 16.7 38 44 0.967 3 CCNA2, IGF2, MAGEA9
7 T BW T1 HG 2.3 7.8 8.1 18.7 35 43 0.975 3 FGFR3, IGF2, MELK
8 C BW - - 1.5 7.6 8.6 12.6 19 40 0.985 0 -
9 T BW T1c HG 1.6 7.5 9.4 15.0 32 42 0.98 5 FGFR3, IGF2, KIF2C, 
MELK, PDZRN3
10 T U T1c+CIS HG 1.1 7.5 13.6 15.0 40 45 0.961 2 CRH, IGF2
11 T U T1b HG 0.8 7.5 12.8 10.1 41 46 0.956 3 CRH, FGFR3, IGF2
12 T U T1 HG 1.2 7.4 10.5 12.3 39 45 0.972 2 CRH, IGF2
13 C BW - - 1.3 7.2 7.9 10.0 28 39 0.976 1 IGF2
14 T BW T1+CIS HG 1.3 6.4 6.4 8.4 35 43 0.975 3 CRH, FGFR3, IGF2
15 C BW - - 0.8 2.8 1,6 1,3 3 13 0.937 0 _
16 C U - - 0 2.5 N/A N/A 8 14 0.95 1 KRT14
17 T U T2 HG 0 2.5 N/A N/A 11 39 0.994 1 CDC2
18 T U T1 HG 0 2.4 N/A N/A 13 41 0.965 3 GJB2, FGFR3, IGF2
19 T U T2+CIS HG 0 2.4 N/A N/A 27 40 0.97 5 CCNA2, CRH, FGFR3, 
IGF2, KRT14
20 T U T2+CIS HG 0 2.3 N/A N/A 31 45 0.938 2 IGF2, TOP2A
21 C BW - - 1.3 N/A 3.8 4.6 18 36 0.943 2 IGF2, FGFR3
22 T BW T2b HG 1.1 N/A 8.6 9.4 40 45 0.968 1 IGF2
Legend/key: Samples are ranked by RIN number. BW, Bladder Washing; CIS, Carcinoma In Situ; C, Control; CT, Cycle Threshold; HG, High Grade; LG, Low Grade; N/A, Non Available; NPA, Non-
Preamplified; PA, Preamplified; RIN, RNA Integrity Number; T, Tumor; U, Urine.BMC Research Notes 2008, 1:21 http://www.biomedcentral.com/1756-0500/1/21
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rectly preamplified and that the preamplification process
maintains relative gene expression levels of the initial
RNA over a broad range of CT values (Table 3).
For some time, it has been believed that degraded RNA
samples were not suitable for gene expression studies.
Nevertheless, many authors have recently reported the use
of this material for gene profiling using DNA microarrays
as well as qRT-PCR approaches [12,15]. In order to inves-
tigate whether RNA degradation influences the efficiency
of preamplification, gene expression measurements from
those samples with a high RNA quality (RIN > 8; n= 6),
those with good RNA quality (5 < RIN < 8; n= 8) and those
with low RNA quality (RIN < 5; n= 6) [16] were compared
(Table 2). The two samples with non available RIN were
excluded from this part of the study. The mean CT decre-
ment after preamplification was very similar in the three
groups of samples; 3.90, 3.68 and 4.00, respectively. As
expected, we initially found that the average number of
validated genes corresponds to the RNA integrity (35.8,
34.6 and 16.5 in high, good and low RNA quality sam-
ples, respectively). The average number of validated genes
Table 3: Number of validated genes of two serial dilutions of 3 cDNA samples before and after their preamplification.
Initial cDNA
25 ng of preamplified cDNA
Sample number N° validated genes (CT ≤ 31) N° validated genes with ΔΔCT outside ± 1.5 r
NPA samples PA samples
23 9 4 6 4 0 . 9 7 8
11 41 46 3 0.956
22 40 45 1 0.968
ng cDNA/port 500 15000
Dilution 1/20 of the initial cDNA
1.25 ng of preamplified cDNA
Sample number N° validated genes (CT ≤ 31) N° validated genes with ΔΔCT outside ± 1.5 r
NPA samples PA samples
21 4 3 8 6 0 . 9 7 2
11 22 40 2 0.967
22 6 39 5 0.988
ng cDNA/port 25 750
Dilution 1/400 of the initial cDNA
0.06 ng of preamplified cDNA
Sample number N° validated genes (CT ≤ 31) N° validated genes with ΔΔCT outside ± 1.5 r
NPA samples PA samples
23 1 7 0 0 . 9 6 2
11 2 27 3 0.883
22 3 20 2 0.932
ng cDNA/port 1.25 37.5
Legend/key: The number of each sample corresponds to the "sample number" indicated in Table 2. CT, Cycle Threshold; NPA, Non-Preamplified; 
PA, Preamplified.BMC Research Notes 2008, 1:21 http://www.biomedcentral.com/1756-0500/1/21
Page 6 of 8
(page number not for citation purposes)
in the three groups of samples after the cDNA preamplifi-
cation was 45.2, 43.9 and 32.8 in high, good and low RNA
quality samples, respectively, resulting from the incre-
ment in the number of validated genes being much higher
in degraded RNA than from high/good quality RNA sam-
ples.
Thus, we have been able to demonstrate that preamplifed
cDNA from samples with different RNA degradation
states is a suitable material for TA analysis, facilitating the
simultaneous analysis of multiple targets in a single exper-
iment from archived pathology specimens in retrospective
studies.
Conclusion
To our knowledge, this is the first quantitative gene
expression report validating that cDNA preamplification
using the TPAMMK prior to TA analysis preserves relative
transcript expression levels of individual genes. The possi-
bility to increase cDNA quantity before its analysis by TA
opens up the possibility of analysing multiple target genes
in a single experiment in those samples that yield scarce
quantities of RNA. Furthermore, this approach is suitable
for preamplifying genes from degraded RNA and low
abundance expressed genes. This combined methodology
could have wide applications in clinical research, where
scarce amounts of degraded RNA are usually obtained and
several genes needs to be quantified in each sample.
Methods
Patients and samples
Ten bladder washings (BW) and 7 voided urine specimens
from patients with pathologically diagnosed bladder can-
cer (BC) [17,18] and 4 BW and 1 urine sample from
patients without history of BC (controls) were collected
between April 2004 and September 2005 after informed
consent (Table 2).
Ice cooled BW or urine samples were mixed with 1/25 vol-
umes of 0.5 M EDTA, pH 8.0 and were centrifuged at 1000
× g for 10 minutes. The cell pellets were re-suspended in 1
ml of TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and
frozen at -80°C until RNA extraction.
RNA extraction and cDNA synthesis
RNAs were extracted using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to manufacturer's instruc-
tions. Total RNA was quantified by spectrophotometric
analysis at 260 nm and RNA degradation was assessed
using the Agilent 2100 Bioanalyzer (Agilent Technologies,
Waldbronn, Germany) [19] (Table 2).
cDNA was synthesized from 1 μg of total RNA using the
High Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, USA, hereafter referred as AB) following man-
ufacturer instructions, except that the final volume of the
reaction was 50 μl.
Multiplex preamplification of cDNA targets
A multiplex PCR preamplification of the 46 specific cDNA
targets and the endogenous control GUSB (Table 1) was
performed using TPAMMK following manufacturer's
instructions (AB). The 47 TaqMan Gene Expression Assays
(AB) were pooled together at 0.2× final concentration.
Subsequently, 12.5 μl of the pooled assay mix (0.2X) were
combined with 25 ng of each cDNA sample and 25 μl of
the TaqMan PreAmp Master Mix (2X) in a final volume of
50 μl (Figure 1). Thermal cycling conditions were as fol-
lows: initial hold at 95°C during 10 min and ten pream-
plification cycles of 15 sec at 95°C and 4 min at 60°C.
For samples n° 2, 11 and 22, two dilutions (1/20 and 1/
400) of the NPA cDNA were prepared and 1.25 μl of each
cDNA dilution (1.25 ng and 0.0625 ng, respectively) were
subsequently preamplified with the same protocol
described above.
TaqMan Arrays (TA)
The NPA and PA target cDNAs were then amplified in sin-
gleplex reactions using TA following manufacturer's rec-
Workflow for the entire preamplification process Figure 1
Workflow for the entire preamplification process. 
Detailed steps are described in the Material and Methods 
section. Briefly, to increase the quantity of the specific cDNA 
targets for gene expression analysis using TaqMan methodol-
ogy, cDNA from the reverse transcription is mixed with 
pooled TaqMan Gene Expression Assays and with TaqMan 
PreAmp MasterMix. After the multiplex preamplification of 
desired cDNA targets, quantitative real time PCR amplifica-
tion of preamplified target cDNAs, using sequence-specific 
primers and TaqMan probes from the TaqMan Gene Expres-
sion Assays and TaqMan Gene Expression Master Mix, is per-
formed.BMC Research Notes 2008, 1:21 http://www.biomedcentral.com/1756-0500/1/21
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ommendations (AB). Commercially available TaqMan
Gene Expression Assays (AB) for all the 46 genes differen-
tially expressed in bladder cancer specimens (data not
shown) and the endogenous control GUSB  were used
(Table 1). Twenty-five μl of NPA cDNAs and 30 μl of PA
cDNAs were mixed with 50 μl of 2× TaqMan Universal
PCR Master Mix (AB) in a final volume of 100 μl. After
loading mixes into the TA ports, cards were centrifuged
twice for 1 min at 1200 rpm, sealed and run in an ABI
PRISM 7900HT SDS with the following thermal condi-
tions: 2 min at 50°C, 10 min at 94.5°C, 40 cycles of dena-
turation at 97°C for 30 sec and annealing and extension
at 59.7°C for 1 min.
Data analysis
Quantitative real time PCR data were processed with SDS
2.1 software package (AB). A defined baseline of 3 to 12
cycles and a defined threshold of 0.35 were used for all the
genes to record the cycle thresholds (CTs). Since precision
on TA starts dropping off at around 30–32 CTs, assays that
yielded a CT > 31 cycles were excluded from the analysis
and comparisons between PA and NPA genes were per-
formed only taking into account those genes with a CT
value ≤ 31 in NPA samples (named validated genes). Data
normalization was carried out with reference gene GUSB.
Linear regression analysis was performed to compare gene
expression data (ΔCT) from NPA targets (ΔCTNPA = CTNPA
target -CTNPA GUSB) vs PA targets (ΔCTPA = CTPA target -CTNPA
GUSB). Those regressions with less than 4 points were
excluded from the analysis. Specific gene preamplification
uniformity was checked calculating the ΔCTNPA  and
ΔCTPA, and determining the ΔΔCT between NPA and PA
targets (ΔΔCT = ΔCTPA -ΔCTNPA). ΔΔCT values close to
zero indicated preamplification uniformity. Targets that
produce ΔΔCT values within ± 1.5 were considered uni-
formly preamplified (TPAMMK Protocol, AB). AE of each
assay was calculated from fluorescent data using the
DART-PCR software version 1.0 [20,21]. Pfaffl (2001) def-
inition for AE has been used [22].
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